Reduction of chronic hepatitis B‐related hepatocellular carcinoma with anti‐viral therapy, including low risk patients
Authors:
Open Access
- 23 August 2016
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 44 (8) , 846-855
Abstract
Summary: Background: Anti‐viral therapy in chronic hepatitis B (CHB) is associated with a reduced risk of hepatocellular carcinoma (HCC) primary described in patients with cirrhosis.Aim: To examine the effects of treatment on HCC incidence in CHB with and without cirrhosis, after adjustment for background risks.Methods: A total of 2255 CHB patients from a US cohort (973 received anti‐viral therapy) and 3653 patients from the community‐based Taiwanese REVEAL‐HBV study, none of whom received treatment. We used Cox proportional hazard models to calculate the risk of developing HCC after adjustment with the previously validated REACH‐B risk score.Results: We found 273 incident cases of HCC. After adjustment, therapy lowered the risk of HCC development in the US treated cohort when compared to the US untreated cohort (HR 0.31; 95% CI: 0.15–0.66; P = 0.002). HCC risk reduction was also confirmed when compared to the REVEAL cohort (HR 0.22; 95% CI: 0.12–0.40; P < 0.001). Each REACH‐B point was associated with a 53% increased risk of HCC (HR 1.53; 95% CI 1.46–1.59; P < 0.001). We found a significant statistical reduction in HCC incidence with therapy regardless of gender, age, cirrhosis status, HBeAg serology, alanine aminotransferase level, REACH‐B score or treatment medication. Therapy was beneficial to those with mildly‐ to moderately elevated HBV DNA levels (>2000 IU/mL) and of even greater benefit to those with levels >200 000 IU/mL.Conclusion: After adjustment for background risk, anti‐viral therapy was associated with a significant reduction in HCC incidence in both community and real‐life clinical cohorts, including in those patients previously thought to be at low risk.Keywords
This publication has 37 references indexed in Scilit:
- Meta‐analysis: the impact of oral anti‐viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis BAlimentary Pharmacology & Therapeutics, 2013
- Hepatitis B in the United States: A major health disparity affecting many foreign-born populationsHepatology, 2012
- Meta‐analysis: reduction in hepatic events following interferon‐alfa therapy of chronic hepatitis BAlimentary Pharmacology & Therapeutics, 2010
- Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic reviewJournal of Hepatology, 2010
- Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis BJournal of Hepatology, 2009
- Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinomaAlimentary Pharmacology & Therapeutics, 2008
- Virologic and Histologic Features of Chronic Hepatitis B Virus-Infected Asymptomatic Patients With Persistently Normal ALTGastroenterology, 2008
- Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinomaJournal of Hepatology, 2007
- Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver DiseaseNew England Journal of Medicine, 2004
- Hepatitis B e Antigen and the Risk of Hepatocellular CarcinomaNew England Journal of Medicine, 2002